Subgroup analyses
| Subgroup . | VTE (47 total) . | Cumulative VTE incidence in % (95% CI) . | SHR (95% CI) . | ATE (9 total) . | Cumulative ATE incidence in % (95% CI) . | SHR (95% CI) . |
|---|---|---|---|---|---|---|
| Tumor type | ||||||
| Melanoma (n = 204) | 16 | 12.9 (6.6-21.4) | 0.99 (0.55-1.80) | 2 | 1.6 (0.3-5.7) | 0.52 (0.11-2.54) |
| Non-small cell lung cancer (n = 162) | 12 | 11.7 (5.4-20.7) | 1.32 (0.69-2.56) | 2 | 1.4 (0.3-4.4) | 1.14 (0.24-5.34) |
| Renal cell carcinoma (n = 74) | 3 | 4.9 (1.2-12.2) | 0.55 (0.17-1.77) | 2 | 1.7 (0.1-7.8) | 1.20 (0.15-9.52) |
| Head and neck squamous cell carcinoma (n = 70) | 4 | 8.7 (2.7-19.2) | 0.90 (0.32-2.49) | 0 | — | — |
| Urothelial (n = 33) | 1 | — | — | 0 | — | — |
| Lymphoma (n = 28) | 1 | — | — | 1 | — | — |
| Hepatocellular cancer (n = 20) | 3 | 15.7 (3.9-34.8) | 2.28 (0.68-7.68) | 0 | — | — |
| Gynecological cancer (n = 18) | 4 | 26.9 (7.7-51.1) | 4.08 (1.43-11.63) | 1 | — | — |
| Sarcoma (n = 17) | 1 | — | — | 0 | — | — |
| Gastrointestinal cancer (upper and lower, n = 15) | 0 | — | — | 0 | — | — |
| Prostate cancer | 0 | — | — | 1 | — | |
| Merkel cell carcinoma (n = 5) | 1 | — | — | 0 | — | — |
| Glioblastoma (n = 2) | 1 | — | — | 0 | — | |
| Immune checkpoint inhibitor agent | ||||||
| Nivolumab (n = 282) | 20 | 9.8 (5.9-14.8) | 1.08 (0.61-1.92) | 4 | 2.5 (0.6-7.0) | 0.85 (0.20-3.60) |
| Pembrolizumab (n = 269) | 17 | 13.9 (5.4-26.4) | 0.89 (0.49-1.61) | 4 | 1.5 (0.5-3.7) | 1.33 (0.37-4.76) |
| Ipilimumab (n = 45) | 7 | 13.6 (5.8-24.7) | 1.02 (0.50-2.09) | 0 | — | — |
| Ipilimumab + nivolumab (n = 40) | 0 | — | — | 0 | — | — |
| Atezolizumab (n = 30) | 3 | 19.9 (3.0-47.4) | 1.36 (0.43-4.26) | 1 | — | — |
| Avelumab (n = 6) | 0 | — | — | 0 | — | — |
| Subgroup . | VTE (47 total) . | Cumulative VTE incidence in % (95% CI) . | SHR (95% CI) . | ATE (9 total) . | Cumulative ATE incidence in % (95% CI) . | SHR (95% CI) . |
|---|---|---|---|---|---|---|
| Tumor type | ||||||
| Melanoma (n = 204) | 16 | 12.9 (6.6-21.4) | 0.99 (0.55-1.80) | 2 | 1.6 (0.3-5.7) | 0.52 (0.11-2.54) |
| Non-small cell lung cancer (n = 162) | 12 | 11.7 (5.4-20.7) | 1.32 (0.69-2.56) | 2 | 1.4 (0.3-4.4) | 1.14 (0.24-5.34) |
| Renal cell carcinoma (n = 74) | 3 | 4.9 (1.2-12.2) | 0.55 (0.17-1.77) | 2 | 1.7 (0.1-7.8) | 1.20 (0.15-9.52) |
| Head and neck squamous cell carcinoma (n = 70) | 4 | 8.7 (2.7-19.2) | 0.90 (0.32-2.49) | 0 | — | — |
| Urothelial (n = 33) | 1 | — | — | 0 | — | — |
| Lymphoma (n = 28) | 1 | — | — | 1 | — | — |
| Hepatocellular cancer (n = 20) | 3 | 15.7 (3.9-34.8) | 2.28 (0.68-7.68) | 0 | — | — |
| Gynecological cancer (n = 18) | 4 | 26.9 (7.7-51.1) | 4.08 (1.43-11.63) | 1 | — | — |
| Sarcoma (n = 17) | 1 | — | — | 0 | — | — |
| Gastrointestinal cancer (upper and lower, n = 15) | 0 | — | — | 0 | — | — |
| Prostate cancer | 0 | — | — | 1 | — | |
| Merkel cell carcinoma (n = 5) | 1 | — | — | 0 | — | — |
| Glioblastoma (n = 2) | 1 | — | — | 0 | — | |
| Immune checkpoint inhibitor agent | ||||||
| Nivolumab (n = 282) | 20 | 9.8 (5.9-14.8) | 1.08 (0.61-1.92) | 4 | 2.5 (0.6-7.0) | 0.85 (0.20-3.60) |
| Pembrolizumab (n = 269) | 17 | 13.9 (5.4-26.4) | 0.89 (0.49-1.61) | 4 | 1.5 (0.5-3.7) | 1.33 (0.37-4.76) |
| Ipilimumab (n = 45) | 7 | 13.6 (5.8-24.7) | 1.02 (0.50-2.09) | 0 | — | — |
| Ipilimumab + nivolumab (n = 40) | 0 | — | — | 0 | — | — |
| Atezolizumab (n = 30) | 3 | 19.9 (3.0-47.4) | 1.36 (0.43-4.26) | 1 | — | — |
| Avelumab (n = 6) | 0 | — | — | 0 | — | — |
Cumulative incidences were only estimated if ≥2 events occurred in a specific subgroup. Otherwise, only the crude number of events is reported. Only entities with a minimum number of 10 patients or occurrence of a thrombotic event are listed. Not listed are small cell lung cancer (n = 3), cancer of unknown primary (n = 2), pleural mesothelioma (n = 4), breast cancer (n = 3), penile carcinoma (n = 1), glioma (n = 1), and thyroid cancer (n = 1).